RT Journal Article
T1 Statin and all-cause mortality in patients receiving anticoagulant therapy for venous thromboembolism. Data from the RIETE registry.
A1 Siniscalchi, Carmine
A1 Quintavalla, Roberto
A1 Rocci, Anna
A1 Riera-Mestre, Antoni
A1 Trujillo-Santos, Javier
A1 Suriñach, José María
A1 Jara-Palomares, Luis
A1 Bikdeli, Behnood
A1 Moustafa, Farès
A1 Monreal, Manuel
A1 RIETE Investigators, 
K1 Death all-causes
K1 Fatal bleeding
K1 Fatal pulmonary embolism
K1 Statins
K1 Venous thomboembolism
AB The clinical outcomes during the course of anticoagulation in patients with venous thromboembolism (VTE) using statins remain controversial. We used the RIETE (Registro Informatizado Enfermedad TromboEmbólica) registry to compare the risk for VTE recurrences, major bleeding or death during anticoagulation, according to the use of statins at baseline. We used propensity score-matching (PSM) to adjust for confounding variables. From February 2009 to January 2018, 32,062 VTE patients were included. Of these, 7,085 (22%) were using statins. Statin users were 10 years older (73±11 vs. 63±19 years, respectively) and more likely to have comorbidities or to be using antiplatelets or corticosteroids at baseline than non-users. During the course of anticoagulation (median, 177 days), 694 patients developed VTE recurrences, 848 bled and 3,169 died (fatal pulmonary embolism 176, fatal bleeding 121). Statin users had a similar rate of VTE recurrences (hazard ratio [HR]: 0.98; 95%CI: 0.82-1.17), a higher rate of major bleeding (HR: 1.29; 95%CI: 1.11-1.50) and a similar mortality rate (HR: 1.01; 95%CI: 0.93-1.10) than non-users. On PSM analysis, statin users had a significantly lower risk for death (HR: 0.62; 95%CI: 0.48-0.79) and a similar risk for VTE recurrences (HR: 0.98; 95%CI: 0.61-1.57) or major bleeding (HR: 0.85; 95%CI: 0.59-1.21) than non-users. During anticoagulation for VTE, patients using statins at baseline had a lower risk to die than non-users.
YR 2019
FD 2019-08-16
LK http://hdl.handle.net/10668/14413
UL http://hdl.handle.net/10668/14413
LA en
DS RISalud
RD May 11, 2025